Quantinno Capital Management LP Acquires 18,716 Shares of Qiagen (NYSE:QGEN)

Quantinno Capital Management LP grew its holdings in shares of Qiagen (NYSE:QGEN) by 31.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 78,707 shares of the company’s stock after purchasing an additional 18,716 shares during the quarter. Quantinno Capital Management LP’s holdings in Qiagen were worth $3,562,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of Qiagen in the 2nd quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after acquiring an additional 243 shares in the last quarter. CWM LLC lifted its holdings in Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC boosted its position in Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on QGEN shares. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $50.80.

Qiagen Trading Down 0.0 %

Shares of QGEN stock opened at $43.42 on Monday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The firm’s fifty day simple moving average is $43.09 and its 200 day simple moving average is $43.64. The firm has a market capitalization of $9.91 billion, a P/E ratio of 111.33, a price-to-earnings-growth ratio of 3.39 and a beta of 0.35.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.